Pfizer Inc.
PFEHealthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −9.68%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. 10-Q filed May 5, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 4, 2025: 18 added · 63 removed · 69 modified; 7 with only figures updated; 2 moved without change
-
Modified · OVERVIEW OF OUR PERFORMANCE, OPERATING AND GLOBAL ECONOMIC ENVIRONMENT
Our Business
and Strategy––Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Our 2025 key priorities are to:through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide.